Shots:

• The first patient has been dosed in a P-II clinical trial to evaluate orelabrutinib (BTK inhibitor) in patients with ITP in China. The therapy is also being studied for MS & SLE
• The studies showed that 70% of patients respond to 1L treatments, some patients are still r/r after combined therapies. The therapy may reduce platelet destruction by inhibiting B cell activation & autoantibody production & has high target selectivity with a safety profile
• Orelabrutinib had received BTD from the US FDA for r/r MCL & NMPA’s approval for r/r CLL / SLL & for r/r MCL. The therapy is currently undergoing in the US & China as monothx. or in combination therapies for MZL, CNSL, WM & DLBCL

 Ref: PR Newswire | Image: Innocare